Related Experiment Video
Updated: Sep 1, 2025
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
A review of osteoarthritis signaling intervention using small-molecule inhibitors
1Division of Rheumatology, Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.
Abstract:
Numerous small-molecule inhibitors (SMIs) have been approved as adjuvant or first-line therapies for malignancies. Based on cancer treatment using SMIs, next-generation SMIs that can be used to optimize the therapeutic index, overcome drug resistance, and establish combination therapies are in development. Osteoarthritis (OA) is the most common chronic joint disease with senescence, and there are various approaches to OA treatment; however, the gold standard treatment is controversial. Therefore, in this manuscript, we demonstrated the potential of using SMIs in OA treatment and described the general strategies for using SMIs in OA treatment.
Insights
Small-molecule inhibitors (SMIs) show promise for treating osteoarthritis (OA). This study explores strategies for using SMIs to optimize OA therapy and overcome treatment challenges.
Area of Science:
- Pharmacology
- Rheumatology
- Oncology
Background:
- Small-molecule inhibitors (SMIs) are established therapies for various malignancies.
- Next-generation SMIs are being developed to enhance efficacy and combat drug resistance in cancer.
- Osteoarthritis (OA) is a prevalent chronic joint disease with limited definitive treatment options.
Purpose of the Study:
- To investigate the potential therapeutic applications of small-molecule inhibitors (SMIs) in osteoarthritis (OA) treatment.
- To outline strategies for leveraging SMIs to improve OA management.
- To address the need for optimized OA treatment approaches.
Main Methods:
- Review of existing literature on small-molecule inhibitors in cancer therapy.
- Analysis of senescence pathways implicated in osteoarthritis.
- Exploration of potential SMI mechanisms relevant to OA pathology.
Main Results:
- Small-molecule inhibitors demonstrate potential for targeting key pathways in osteoarthritis.
- Strategies for optimizing SMI use in OA include enhancing therapeutic index and overcoming resistance.
- Combination therapies with SMIs may offer novel treatment avenues for OA.
Conclusions:
- Small-molecule inhibitors represent a promising therapeutic class for osteoarthritis.
- Further research into SMI strategies can advance OA treatment paradigms.
- The application of SMIs in OA management warrants continued investigation.
